Approval · Notice of Compliance 117 · 2004
LEVAQUIN: Notice of Compliance 117
Issued February 6, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 117
- Date
- February 6, 2004
- Company
- Janssen-Ortho Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: treatment of nosocomial pneumonia using a once daily 750 mg dose for 7 to 14 days
- Therapeutic class
- Anti-bacterial agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LEVAQUIN | Not yet assigned | — |
Medicinal ingredients
- LEVOFLOXACIN 250 MG per TAB
- LEVOFLOXACIN 500 MG per TAB
- LEVOFLOXACIN 750 MG per TAB
- LEVOFLOXACIN 25 MG per ML
- LEVOFLOXACIN 5 MG per ML